COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,237 Articles (22,733 medRxiv, 8,504 bioRxiv)

Most recent first Previous |  Page 1253: Articles 12521-12530  | Next

The anticipated artificial increase in life expectancy from COVID-19
Kissler, S. M., Grad, Y.
10.1101/2021.09.09.21263351 — Posted: 2021-09-11
The contribution of hospital-acquired infections to the COVID-19 epidemic in England in the first half of 2020
Knight, G. M., Pham, T. M., Stimson, J., Funk, S., Jafari, Y., Pople, D., Evans, S., Yin, M., Brown, C., Bhattacharya, A., Hope, R., Semple, M. G., ISARIC4C Investigators, , CMMID COVID-19 working group, , Read, J. M., Cooper, B. S., Robotham, J. V.
10.1101/2021.09.02.21262480 — Posted: 2021-09-10
Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants
Wirnsberger, G., Monteil, V., Eaton, B., Postnikova, E., Murphy, M., Braunsfeld, B., Crozier, I., Kricek, F., Niederhoefer, J., Schwarzboeck, A., Breid, H., Sanchez Jimenez, A., Bugajska-Schretter, A., Dohnal, A., Ruf, C., Gugenberger, R., Hagelkrueys, A., Montserrat, N., Holbrook, M., Oostenbrink, C., Shoemaker, R. H., Mirazimi, A., Penninger, J. M.
10.1101/2021.09.10.459744 — Posted: 2021-09-10 Discussion: Onsite
Pharmacological perturbation of intracellular dynamics as a SARS-CoV-2 antiviral strategy
Bakhache, W., Partiot, E., Lucansky, V., Bare, Y., Bonaventure, B., Goujon, C., Bories, C., Deffieu, M. S., Gaudin, R.
10.1101/2021.09.10.459410 — Posted: 2021-09-10
Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns
Rothen, D. A., Krenger, P. S., Nonic, A., Balke, I., Vogt, A.-C., Chang, X., Manenti, A., Vedovi, F., Resevica, G., Walton, S., Zeltins, A., Montomoli, E., Vogel, M., Bachmann, M. F., Mohsen, M. O.
10.1101/2021.09.10.459749 — Posted: 2021-09-10
Differential antibody dynamics to SARS-CoV-2 infection and vaccination
Chen, Y., Tong, P., Whiteman, N. B., Moghaddam, A. S., Zuiani, A., Habibi, S., Gautam, A., Xiao, T., Cai, Y., Chen, B., Wesemann, D. R.
10.1101/2021.09.09.459504 — Posted: 2021-09-10
Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
Barsi, S., Papp, H., Valdeolivas Urbelz, A., Toth, D. J., Kuczmog, A., Madai, M., Hunyady, L., Varnai, P., Saez-Rodriguez, J., Jakab, F., Szalai, B.
10.1101/2021.09.10.459786 — Posted: 2021-09-10
pH-dependent polymorphism of the structure of SARS-CoV-2 nsp7
Lee, Y., Tonelli, M., Rahimi, M., Anderson, T. K., Kirchdoerfer, R. N., Henzler-Wildman, K., Lee, W.
10.1101/2021.09.10.459800 — Posted: 2021-09-10
COVID-19 Vaccine Concerns about Safety, Effectiveness and Policies in the United States, Canada, Sweden, and Italy among Unvaccinated Individuals
Piltch-Loeb, R., Harriman, N., Healey, J., Bonetti, M., Toffolutti, V., Testa, M., Su, M., Savoia, E.
10.1101/2021.09.09.21263328 — Posted: 2021-09-10
Epidemic Models for COVID-19 during the First Wave from February to May 2020: a Methodological Review
Garin, M., Limnios, M., Nicolai, A., Bargiotas, I., Boulant, O., Chick, S. E., Dib, A., Evgeniou, T., Fekom, M., Kalogeratos, A., Labourdette, C., Ovchinnikov, A., Porcher, R., Pouchol, C., Vayatis, N.
10.1101/2021.09.02.21263033 — Posted: 2021-09-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).